Sudo

Sudo Biosciences is a biopharmaceutical company dedicated to designing and developing novel drugs that transform patients' lives. The company’s programs target the pseudokinase domain of tyrosine kinase 2 (TYK2). TYK2 is a key mediator in cytokine signaling pathways and is associated with various immune-mediated inflammatory conditions. Sudo’s next-generation TYK2 inhibitor pipeline includes a potential first-in-class brain-penetrant candidate for the treatment of multiple sclerosis and neurodegenerative diseases involving potential neuroinflammation, as well as a potential first-in-class topical candidate for the treatment of immune-mediated dermatological conditions. Both candidates are expected to enter clinical trials in 2024.